Key Takeaways STXS partners with CardioFocus to create a robotic PFA system for cardiac arrhythmia treatment.The collaboration merges robotic precision with advanced PFA technology for safer, faster ablations.STXS gains access to the expanding PFA market, enhancing its robotics portfolio and growth potential. Stereotaxis (STXS) recently partnered with CardioFocus to develop the first robotic Pulsed Field Ablation (PFA) system for treating cardiac arrhythmias. The collaboration brings together Stereotaxis’ r ...

Core Insights - Stereotaxis and CardioFocus have entered a Collaboration Agreement to advance robotic Pulsed Field Ablation (PFA) technology for cardiac arrhythmias [1][2][3] Company Overview - Stereotaxis is a leader in surgical robotics for minimally invasive endovascular interventions, having treated over 150,000 patients globally [5] - CardioFocus specializes in pulsed field ablation treatment for cardiac disorders, particularly atrial fibrillation, and has developed the Centauri PFA System, which has been used on over 9,000 patients in Europe [6] Collaboration Details - The collaboration aims to combine the Centauri PFA System with Stereotaxis' MAGiC robotic cardiac ablation catheter, enhancing the efficiency and safety of cardiac ablation procedures [2][3] - Extensive bench and preclinical testing have shown that the combination of Centauri and MAGiC delivers safe and efficient lesion delivery, including durable lesions in ventricular tissue [3] Clinical and Regulatory Progress - The partnership supports advancing the joint solution to clinical trials, facilitating regulatory compatibility and commercial availability [3] - Both companies anticipate transitioning to first human use and advancing the regulatory process in the coming months [4]